Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Ascendis Pharma A/S

Equities

ASND

US04351P1012

Real-time Estimate Cboe BZX
Other stock markets
 02:12:31 2024-05-13 pm EDT 		5-day change 1st Jan Change
132.6 USD -0.67% Intraday chart for Ascendis Pharma A/S -1.07% +5.25%
03:31pm Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH MT
May. 10 Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH
MT
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
AQ
Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing
MT
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
AQ
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
MT
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises
MT
Ascendis Pharma A/S : Form 6-K
PU
Transcript : Ascendis Pharma A/S, Q1 2024 Earnings Call, May 02, 2024
Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M
MT
Ascendis Pharma Reports First Quarter 2024 Financial Results
AQ
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading
MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%
MT
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
AQ
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
MT
Ascendis Pharma - United Kingdom's MHRA Approves YORVIPATH in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
AQ
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism
MT
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
AQ
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ASND Stock
  4. News Ascendis Pharma A/S
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW